These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Lymphoproliferative disease of the central nervous system in a patient with dermatomyositis on immunomodulation therapy. Cykowski MD; Fung KM; Desousa E; Parham DM; Zhao L; Stolzenberg ED Clin Neuropathol; 2013; 32(2):135-8. PubMed ID: 23211434 [No Abstract] [Full Text] [Related]
46. Are natural killer cells the key to treating Epstein-Barr virus-associated lymphoproliferative disorders? Robertson MJ J Clin Invest; 2001 Sep; 108(6):801-2. PubMed ID: 11560947 [No Abstract] [Full Text] [Related]
47. EBV-related lymphoproliferative disorders in immunocompetent patients. Oosterveld M; Lesterhuis WJ; MacKenzie M; van Krieken JH Leukemia; 2003 Dec; 17(12):2537-8. PubMed ID: 14523463 [No Abstract] [Full Text] [Related]
48. Gene-corrected human Munc13-4-deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice. Soheili T; Rivière J; Ricciardelli I; Durand A; Verhoeyen E; Derrien AC; Lagresle-Peyrou C; de Saint Basile G; Cosset FL; Amrolia P; André-Schmutz I; Cavazzana M Blood; 2016 Dec; 128(24):2859-2862. PubMed ID: 27799161 [No Abstract] [Full Text] [Related]
49. Interleukin-21 overexpression dominates T cell response to Epstein-Barr virus in a fatal case of X-linked lymphoproliferative syndrome type 1. Ortega C; Estévez OA; Fernández S; Aguado R; Rumbao JM; Gonzalez T; Pérez-Navero JL; Santamaría M Clin Vaccine Immunol; 2013 May; 20(5):765-71. PubMed ID: 23467775 [TBL] [Abstract][Full Text] [Related]
50. Improving T cell therapy for cancer. Leen AM; Rooney CM; Foster AE Annu Rev Immunol; 2007; 25():243-65. PubMed ID: 17129181 [TBL] [Abstract][Full Text] [Related]
51. Minimal T-cell requirements for triggering haemophagocytosis associated with Epstein-Barr virus-driven B-cell proliferation: a clinical case study. Daikeler T; Tzankov A; Hoenger G; Gasser O; Tyndall A; Gratwohl A; Hess C Ann Rheum Dis; 2011 Jul; 70(7):1338-9. PubMed ID: 21216813 [No Abstract] [Full Text] [Related]
52. Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Fissolo N Mult Scler; 2014 Oct; 20(11):1545. PubMed ID: 24622348 [No Abstract] [Full Text] [Related]
53. Gene transfer and the treatment of haematological malignancy. Brenner MK J Intern Med; 2001 Apr; 249(4):345-58. PubMed ID: 11298855 [TBL] [Abstract][Full Text] [Related]
54. Successful Bone Marrow Transplantation for XMEN: Hemorrhagic Risk Uncovered. Dimitrova D; Rose JJ; Uzel G; Cohen JI; Rao KV; Bleesing JH; Kanakry CG; Kanakry JA J Clin Immunol; 2019 Jan; 39(1):1-3. PubMed ID: 30470981 [No Abstract] [Full Text] [Related]
55. [Behavior of antigen-specific CD8+ T cells in Epstein-Barr virus-related disease]. Kuzushima K Uirusu; 2001 Jun; 51(1):43-9. PubMed ID: 11565264 [No Abstract] [Full Text] [Related]
56. [Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes in EBV-related diseases]. Kuzushima K Rinsho Ketsueki; 2000 Jun; 41(6):487-90. PubMed ID: 10921347 [No Abstract] [Full Text] [Related]
57. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation. Torre-Cisneros J; Román J; Torres A; Herrera C; Caston JJ; Rivero A; Mingot E; Rojas R; Martín C; Martínez F; Gómez P J Infect Dis; 2004 Nov; 190(9):1596-9. PubMed ID: 15478063 [TBL] [Abstract][Full Text] [Related]